{"url_path":"/sec/mirm/8-k/2026-04-27/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1759425/0001193125-26-179048-index.html","accession_number":"0001193125-26-179048","cik":"0001759425","ticker":"MIRM","issuer_name":"Mirum Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1759425/0001193125-26-179048-index.html","primary_entity_key":"0001759425","primary_entity_name":"Mirum Pharmaceuticals, Inc."},"word_count":761,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nOn April 27, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an investigational monoclonal antibody designed to bind hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV).\n\nThe Phase 2b portion of the AZURE-1 study included the first 53 patients evaluated at Week 24 of treatment.\n\nAt Week 24, treatment with brelovitug demonstrated robust antiviral activity across both dose groups. 100% of patients in the 300 mg once weekly (QW) arm and 75% of patients in the 900 mg once every four weeks (Q4W) arm achieved virologic response (≥2 log10 reduction in HDV RNA from baseline or undetectable HDV RNA [<LLOQ, TND]), as compared to 0% in the delayed treatment arm.\n\nConsistent with these antiviral effects, the primary composite endpoint of virologic response and alanine aminotransferase (ALT) normalization was achieved in 45% and 35% of patients in the 300 mg QW and 900 mg Q4W arms, respectively, as compared to 0% of patients in the delayed treatment arm. After 24 weeks of treatment, further reductions in ALT and HDV RNA levels have been observed. These results support the potential of brelovitug as a single agent therapy to treat HDV.\n\nThe efficacy results by treatment arm in the Phase 2b portion of AZURE-1 at Week 24 are presented below in Key Efficacy Endpoints.\n\nTreatment with brelovitug was well tolerated across dose groups. The safety profile summary is presented below in Summary of Safety.\n\nThe full results from the Phase 2b portion of the AZURE-1 study will be presented in a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026. Topline data from the Phase 3 AZURE-1 and AZURE-4 studies are expected in H2 2026, with potential BLA submission and commercial launch in the U.S. in 2027.\n\nKey Efficacy Endpoints\n\n \n\nEndpoint\n\n  \n300 mg QW\n(n=20)\n \n900 mg Q4W\n(n=20)\n \nDelayed\nTreatment Arm\n(n=12)\n\nVirologic Response\n\n  \n\n \n\n \n\n(HDV RNA ≥2 log10 reduction or TND)\n\n  \n100%\n \n75%\n \n0%\n\nHDV RNA <LLOQ, TND\n  \n30%\n \n5%\n \n0%\n\nALT Normalization\n  \n45%\n \n40%\n \n8%\n\nPrimary Endpoint\n  \n\n \n\n \n\n(Virologic Response + ALT Normalization)\n\n  \n45%\n \n35%\n \n0%\n\nP-value*\n\n  \n0.003\n \n0.024\n \n\nFull analysis set, participants receiving at least one post baseline efficacy assessment\n\n*\n\nP-values compare each treatment group against delayed treatment using a stratum-adjusted Cochran-Mantel-Haenszel (CMH) test.\n\n \n\n2\n\nSummary of Safety\n\n \n\nParticipants who experienced, n (%)\n\n  \n300 mg QW\nN=21\n \n \n900 mg Q4W\nN=20\n \n \nDelayed\nTreatment Arm\nN=12\n \n\nAEs\n\n  \n\n \n\n \n\nAny\n\n  \n \n11 (52)\n \n \n \n10 (50)\n \n \n \n3 (25)\n \n\nRelated to treatment\n\n  \n \n7 (33)\n \n \n \n7 (35)\n \n \n \n0\n \n\nGrade 3+\n\n  \n\n \n\n \n\nAny\n\n  \n \n1 (5)†\n \n \n \n0\n \n \n \n0\n \n\nRelated to treatment\n\n  \n \n0\n \n \n \n0\n \n \n \n0\n \n\nSerious\n\n  \n\n \n\n \n\nAny\n\n  \n \n0\n \n \n \n1 (5)#\n \n \n \n0\n \n\nRelated to treatment\n\n  \n \n0\n \n \n \n0\n \n \n \n0\n \n\nAE Leading to Discontinuation of study drug\n\n  \n \n0\n \n \n \n0\n \n \n \n0\n \n\nInjection site reactions\n\n  \n \n3 (14)\n \n \n \n4 (20)\n \n \n \n0\n \n\nFlu-like Symptoms\n\n  \n \n0\n \n \n \n1 (5)\n \n \n \n0\n \n\n \n\n† \n\nGrade 3 AE of musculoskeletal pain, not related\n\n# \n\nHospitalization for liver cirrhosis, class B, in a patient with recent history of ascites and hypoalbuminemia, not related and resolved\n\nForward-Looking Statements\n\nCertain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements regarding the potential benefits of brelovitug and the expected timing of topline data for the AZURE studies and potential BLA submission and commercial launch. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of these results will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties associated with research and development of pharmaceutical product candidates, as well as risks and uncertainties inherent in the Company’s business, including those described in the Company’s other filings with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.\n\n \n\n3\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \nMirum Pharmaceuticals, Inc.\n\nDate: April 27, 2026\n \n\n \nBy:\n \n\n/s/ Christopher Peetz\n\n \n\n \n\n \nChristopher Peetz\n\n \n\n \n\n \nChief Executive Officer\n\n \n\n4"}